NeuPath Health Inc. - Executive Chair, Dianne Carmichael
Executive Chair, Dianne Carmichael
Source: Dianne Carmichael
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • NeuPath Health Inc. (NPTH) has announced a new strategic growth plan to accelerate its platform
  • NeuPath is a vertically integrated health care provider helping restore function for patients impacted by chronic pain, spinal injuries, sports-related injuries, and concussions
  • Patients and stakeholders should expect to see new solutions to ease a patient’s journey
  • Dianne Carmichael is now Executive Chair supported by Joseph Walewicz as the new Chief Business Officer
  • NeuPath Health Inc. (NPTH) is up 20.00 per cent and is trading at $0.30 per share as of 2:25 p.m. ET

NeuPath Health (NPTH) has announced a strategic growth plan to accelerate its platform for Canadian patients with musculoskeletal conditions.

NeuPath is a vertically integrated health care provider helping restore function for patients impacted by chronic pain, spinal injuries, sports-related injuries, and concussions.

With equity ownership in seventeen clinics in Ontario and Alberta, NeuPath is building out a large-scale network to better serve patients across Canada as it sees its 14th consecutive positive adjusted EBITA next month.

NeuPath believes recently identified opportunities will provide a broader field of care and could be done across Canada to start with.

The company stated its patients and stakeholders should expect to see new tools and solutions that help ease the navigation of a coordinated patient journey towards even further improved patient outcomes. New tools are allegedly being deployed in the near term and include digital tools, navigation, and fluoroscopy suites.

As a part of the new growth plan, Dianne Carmichael has accepted the newly created role of Executive Chair and will be supported by Joseph Walewicz in the new role of Chief Business Officer.

“We all know how important healthcare is, yet so many people find the treatment journey to be complex and riddled with delays… we have a solid base to further broaden our offering in scope and geography, ultimately delivering the best care to more patients,” Carmichael said.

NeuPath Health Inc. (NPTH) is up 20.00 per cent and is trading at $0.30 per share as of 2:25 p.m. ET.


More From The Market Herald

" UniDoc (CSE:UDOC) signs agreement to provide telehealth services in Kenya

UniDoc Health (UDOC) has signed a master equipment deployment and services agreement with Claron Health to provide telehealth services in Kenya.
InnoCan - Founder and CEO, Iris Bincovich.

" Innocan Pharma (CSE:INNO) approaches 100 per cent CBD bioavailability for its LPT CBD liposomal delivery platform

Innocan Pharma (INNO) has announced results from a clinical study on dogs suffering from pain.
Microbix Biosystems Inc. - Senior Vice President of Sales and Business, Phil Casselli.

" Microbix (TSX:MBX) signs QAPs supply agreement

Microbix Biosystems (MBX) has signed a purchase and supply agreement for its Quality Assurance Program (QAP) products.
Tetra Bio Pharma Inc - CEO & CRO, Guy Chamberland

" Tetra Bio-Pharma (TSX:TBP) shares preclinical results from COVID 19 infection studies

Cannabis-derived drug developer, Tetra Bio-Pharma Inc. (TBP), shared positive preclinical results from live COVID-19 infection studies and a septic lung model.